Christoph U. Correll, MD
Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York; Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Hempstead, New York; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; German Center for Mental Health (DZPG), partner site Berlin, Berlin, Germany
Academic Highlights
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report
August 13, 2025
A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in bipolar type I disorder.
Academic Highlights
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report
August 13, 2025
A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in schizophrenia.
Original Research
The Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US
August 11, 2025
Medical Expenditure Panel Survey data showed that over half of adults with schizophrenia report cognitive impairments, which were associated with higher healthcare costs and lower quality of life.
Academic Highlights
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
June 13, 2025
A consensus panel reviews the pharmacokinetic advantages and clinical utility of long-acting injectable aripiprazole monohydrate to optimize treatment for schizophrenia and bipolar I disorder.
Insights
What are the Efficacy and Safety of Muscarinic Receptor Modulators in Patients With Schizophrenia?
November 19, 2024
In this video, Dr. Correll examines the therapeutic potential of the muscarinic receptor system in schizophrenia treatment. He discusses how targeting muscarinic receptors may address cognitive and functional impairments,...
Insights
What is the Place of Muscarinic Receptor Modulators in the Clinical Care of Patients With Schizophrenia?
November 19, 2024
This video features Dr. Christoph Correll discussing the clinical application of muscarinic receptor modulators in schizophrenia treatment. He explores their unique mechanism of action, compares them to traditional antipsychotics,...
